1. Home
  2. KIO vs RZLT Comparison

KIO vs RZLT Comparison

Compare KIO & RZLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo KKR Income Opportunities Fund

KIO

KKR Income Opportunities Fund

SELL

Current Price

$10.04

Market Cap

455.8M

Sector

Finance

ML Signal

SELL

Logo Rezolute Inc. (NV)

RZLT

Rezolute Inc. (NV)

HOLD

Current Price

$3.98

Market Cap

471.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KIO
RZLT
Founded
N/A
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
455.8M
471.0M
IPO Year
2011
2011

Fundamental Metrics

Financial Performance
Metric
KIO
RZLT
Price
$10.04
$3.98
Analyst Decision
Strong Buy
Analyst Count
0
11
Target Price
N/A
★ $9.80
AVG Volume (30 Days)
339.8K
★ 1.4M
Earning Date
01-01-0001
11-17-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 23.47
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$2,214.20
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.70
$1.07
52 Week High
$12.12
$11.46

Technical Indicators

Market Signals
Indicator
KIO
RZLT
Relative Strength Index (RSI) 41.47 48.00
Support Level $9.74 $3.69
Resistance Level $11.26 $5.36
Average True Range (ATR) 0.11 0.28
MACD 0.04 0.01
Stochastic Oscillator 70.97 66.67

Price Performance

Historical Comparison
KIO
RZLT

About KIO KKR Income Opportunities Fund

KKR Income Opportunities Fund operates as a closed-end registered management investment company. The Fund's main objective is to generate a high level of current income, with a secondary objective of capital appreciation. The company invests in a portfolio of loans and fixed-income instruments of U.S. and non-U.S. issuers. The company will invest at least 80% of its Managed Assets in loans and fixed-income instruments or other instruments, including derivative instruments, with similar economic characteristics under normal market conditions.

About RZLT Rezolute Inc. (NV)

Rezolute Inc is a late-stage rare disease company focused on developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism. Its main clinical asset, Ersodetug, is a potential treatment for refractory hypoglycemia caused by multiple forms of hyperinsulinism. The company has a single reportable segment, which includes all of its activities as a clinical-stage biopharmaceutical company.

Share on Social Networks: